Table 1.
Association of HMMR expression and demographic and clinical characteristics in patients with gliomas
| Characteristic | TCGA | CGGA | ||||
|---|---|---|---|---|---|---|
| Low | High | p | Low | High | p | |
| n | 348 | 348 | 346 | 347 | ||
| Gender, n (%) | 0.592 | 0.668 | ||||
| Female | 153 (22%) | 145 (20.8%) | 144 (20.8%) | 151 (21.8%) | ||
| Male | 195 (28%) | 203 (29.2%) | 202 (29.1%) | 196 (28.3%) | ||
| Age, meidan (IQR) | 40 (32, 51) | 53 (38, 63) | < 0.001 | 42 (34, 50.75) | 43 (34.25, 53) | 0.246 |
| Age, n (%) | < 0.001 | 0.21 | ||||
| < = 60 | 312 (44.8%) | 241 (34.6%) | 316 (45.7%) | 305 (44.1%) | ||
| > 60 | 36 (5.2%) | 107 (15.4%) | 30 (4.3%) | 41 (5.9%) | ||
| WHO grade, n (%) | < 0.001 | < 0.001 | ||||
| G2 | 182 (28.7%) | 42 (6.6%) | 129 (18.6%) | 59 (8.5%) | ||
| G3 | 115 (18.1%) | 128 (20.2%) | 132 (19.1%) | 123 (17.8%) | ||
| G4 | 9 (1.4%) | 159 (25%) | 85 (12.3%) | 164 (23.7%) | ||
| IDH status, n (%) | < 0.001 | 0.006 | ||||
| WT | 45 (6.6%) | 201 (29.3%) | 114 (17.8%) | 172 (26.8%) | ||
| Mut | 300 (43.7%) | 140 (20.4%) | 182 (28.3%) | 174 (27.1%) | ||
| 1p/19q codeletion, n (%) | < 0.001 | 0.134 | ||||
| codel | 121 (17.6%) | 50 (7.3%) | 74 (11.9%) | 71 (11.4%) | ||
| non-codel | 226 (32.8%) | 292 (42.4%) | 208 (33.4%) | 270 (43.3%) | ||
| OS event, n (%) | < 0.001 | < 0.001 | ||||
| Alive | 287 (41.2%) | 137 (19.7%) | 175 (26.4%) | 91 (13.7%) | ||
| Dead | 61 (8.8%) | 211 (30.3%) | 156 (23.5%) | 241 (36.3%) | ||
| DSS event, n (%) | < 0.001 | |||||
| Alive | 288 (42.7%) | 143 (21.2%) | ||||
| Dead | 53 (7.9%) | 191 (28.3%) | ||||
| PFI event, n (%) | < 0.001 | |||||
| Alive | 237 (34.1%) | 113 (16.2%) | ||||
| Dead | 111 (15.9%) | 235 (33.8%) | ||||
OS Overall survival, DSS Disease specific survival, PFI Progress free interval